Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study-MedSci.cn

Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study

Tedeschi, A; Cheah, CY; Opat, SS; Verner, E; Magnano, L; Epperla, N; Hilger, J; Fang, YQ; Simpson, D; Guo, HY; Anderson, MA

BLOOD, 2023; 142 ():

科室
- - 订阅+
  - 更多科室
工具
服务